Cell

EQS-News: IBU-tec Advances Development in Sodium-Ion Battery Research Making Further Progress

Retrieved on: 
Wednesday, March 13, 2024

Among other things, IBU-tec is currently making progress in expanding production towards larger volumes and is pushing ahead with research projects.

Key Points: 
  • Among other things, IBU-tec is currently making progress in expanding production towards larger volumes and is pushing ahead with research projects.
  • IBU-tec has already successfully completed the development and production of phase-pure cathode active material made of sodium manganese layer oxide.
  • In the next step of the research project, IBU-tec is testing the cycle stability of the cathode in full cells and further optimizing it.
  • Ulrich Weitz, Managing Director of IBUvolt battery materials: "With the further development of innovative battery materials, we are securing the future viability of IBU-tec.

EQS-News: Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment

Retrieved on: 
Wednesday, March 13, 2024

Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment

Key Points: 
  • Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment
    The issuer is solely responsible for the content of this announcement.
  • Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment
    Berlin Cures, a clinical-stage biotechnology firm, advances innovative treatment aimed at combating Long COVID, currently impacting over 100 million people globally.
  • The ongoing Phase II clinical trial in Long COVID seeks to deliver conclusive and reliable results on the drug's effectiveness and safety for patients.
  • With the ongoing Phase II trial focusing on Long COVID, Berlin Cures continues to seek additional investments and partnerships to advance this groundbreaking opportunity.

EQS-News: ANDRITZ reports record results for 2023

Retrieved on: 
Wednesday, March 13, 2024

In 2023, international technology group ANDRITZ again achieved the best results in its history.

Key Points: 
  • In 2023, international technology group ANDRITZ again achieved the best results in its history.
  • In the fourth quarter of 2023, ANDRITZ received orders for major pumped storage projects in Austria and Greece.
  • Revenue developed very favorably in 2023, reaching a new record level of 8,660.0 MEUR (+14.8% compared to 2022: 7,542.9 MEUR).
  • The operating result (EBITA) increased in line with revenue and reached 741.9 MEUR, also a record level (+14.4% compared to 2022: 648.5 MEUR).

EQS-News: LION E-Mobility: Delivery of first battery packs with high performance SVolt technology expected in Q4 2024

Retrieved on: 
Wednesday, March 13, 2024

Thus, SVolt will develop two new cells directly for LION Smart, a fully-owned subsidiary of LION E-Mobility AG.

Key Points: 
  • Thus, SVolt will develop two new cells directly for LION Smart, a fully-owned subsidiary of LION E-Mobility AG.
  • Shipping of the battery packs with the SVolt cell technology is expected to start in Q4 2024.
  • The high performance battery packs will integrate both NCM (NMX) High Energy as well as LFP cells.
  • In this respect, LION and SVolt will regularly exchange information on technological innovations and co-operate in the development of new battery packs.

EQS-News: EcoGraf Limited: 127% Increase in the Epanko Mineral Resource

Retrieved on: 
Wednesday, March 13, 2024

The Mineral Resource shows a significant increase in tonnes for the Inferred, Indicated and Measured categories of the block model, compared to the previously reported Mineral Resource in 2023.

Key Points: 
  • The Mineral Resource shows a significant increase in tonnes for the Inferred, Indicated and Measured categories of the block model, compared to the previously reported Mineral Resource in 2023.
  • The increase in the Measured volumes result from infill drilling of gaps within the Indicated Resource of the Western Zone.
  • The Mineral Resource infill drilling targeted the Inferred northern and southern parts of the Epanko Western Zone, with a combination of RC and DD drilling.
  • Figure 4 shows a long section through the Epanko West deposit, showing the updated Mineral Resource classification categories applied to the block model.

Zenith Epigenetics Proudly Supports Rare Disease Day

Retrieved on: 
Thursday, February 29, 2024

ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications

Key Points: 
  • Calgary, Alberta--(Newsfile Corp. - February 29, 2024) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") announces its support of Rare Disease Day by highlighting our expanded development efforts of BET inhibitor ZEN-3694 for rare oncology diseases.
  • Rare Disease Day takes place every year on the last day of February, with this leap year day being the rarest of all Rare Disease Days.
  • This event is a global movement to promote equity in healthcare, and access to diagnosis and therapies for individuals living with rare diseases.
  • We are very pleased that NUT carcinoma patients receiving ZEN-3694 in clinical trial and compassionate use settings have benefitted from our drug," said Donald McCaffrey, CEO of Zenith Epigenetics.

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

Retrieved on: 
Monday, March 11, 2024

BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported positive proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics.

Key Points: 
  • BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported positive proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics.
  • Akribion Genomics, a German-based biotechnology start-up, is focused on a CRISPR-derived molecular complex for cancer treatment.
  • TransCode and Akribion are collaborating to develop a technology that combines Akribion’s cell-killing G-dase E, a Class 2 CRISPR nuclease, with TransCode's TTX nucleic acid delivery platform.
  • These studies also indicate that TTX-G-dase E ribonucleoprotein complexes could be taken up by cancer cells, inducing cancer cell death.

NAPIGEN, Inc. Secures U.S. Patent, Awarded USDA SBIR Grant

Retrieved on: 
Monday, March 11, 2024

The patented claims of US11920140 are directed to methods for altering the genomes of mitochondria or plastids.

Key Points: 
  • The patented claims of US11920140 are directed to methods for altering the genomes of mitochondria or plastids.
  • The mitochondria, also known as the powerhouses of cells, are critical components of plant, fungal, algal, and animal cells.
  • It is the third SBIR grant the company has received since its founding in 2016.
  • NAPIGEN, Inc. expects to complete a Series A financing this year to advance partnerships with agricultural companies to bring products to market.

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

Retrieved on: 
Thursday, March 7, 2024

These data, which highlight the platform’s robust anti-tumor activity against gastric cancer will be presented on April 9th, 2024.

Key Points: 
  • These data, which highlight the platform’s robust anti-tumor activity against gastric cancer will be presented on April 9th, 2024.
  • Celularity is developing a platform to combine a broad portfolio of cell therapies with various approved antibodies to address multiple cancers and other conditions.
  • Celularity’s preclinical asset, PT-CD16VS, is initially being developed in combination with trastuzumab, a cancer drug, for treating HER2-positive cancers.
  • “These data demonstrate the promise and potential of combining Celularity’s cell therapy assets with currently available therapies to address difficult-to-treat cancers,” said Dr. Robert Hariri, Celularity’s CEO and Founder.

TOMI Expands SteraMist iHP Corporate Service Contracts and Clients

Retrieved on: 
Thursday, March 7, 2024

FREDERICK, Md., March 07, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced an expansion in its SteraMist iHP Corporate Service contracts, reaffirming its position as a leading provider of decontamination services to corporate clients in the life sciences industry.

Key Points: 
  • FREDERICK, Md., March 07, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced an expansion in its SteraMist iHP Corporate Service contracts, reaffirming its position as a leading provider of decontamination services to corporate clients in the life sciences industry.
  • SteraMist iHP technology is becoming the standard decontamination technology in the life sciences sector and academic institutions with a broad spectrum of clients equipped with mobile systems, custom integrations, and service contracts.
  • In a notable development, Rising Pharmaceuticals has entered into an ongoing annual contract with TOMI’s SteraMist iHP Corporate Service following the acquisition of a building previously serviced by the team.
  • SteraMist iHP Corporate Service managed to decontaminate our entire facility quickly without causing harm to the infrastructure or our sensitive equipment.